Download 2579-2588 March 15, 2007

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Blood type wikipedia , lookup

Plateletpheresis wikipedia , lookup

Jehovah's Witnesses and blood transfusions wikipedia , lookup

Lymphopoiesis wikipedia , lookup

Blood bank wikipedia , lookup

Hemorheology wikipedia , lookup

Transcript
Chaetocin: a promising new antimyeloma agent with in
vitro and in vivo activity mediated via imposition of
oxidative stress
by Crescent R. Isham, Jennifer D. Tibodeau, Wendy Jin, Ruifang Xu, Michael M.
Timm, and Keith C. Bible
Blood
Volume 109(6):2579-2588
March 15, 2007
©2007 by American Society of Hematology
Chaetocin bears chemical structural similarity to the acetylated histone lysine moiety mimicked
by many histone deacetylase inhibitors (HDACIs) and has antimyeloma activity in vitro yet does
not appreciably alter levels of acetylated histone H3 in myeloma c...
Crescent R. Isham et al. Blood 2007;109:2579-2588
©2007 by American Society of Hematology
Chaetocin kills myeloma cells in vitro via induction of morphologic apoptosis accompanied by
loss of mitochondrial membrane potential, PARP cleavage, and DNA ladder formation.
Crescent R. Isham et al. Blood 2007;109:2579-2588
©2007 by American Society of Hematology
Chaetocin kills freshly collected sorted patient CD138+ myeloma cells while sparing matched
normal CD138− bone marrow leukocytes, normal B cells, and neoplastic B-CLL (chronic
lymphocytic leukemia) cells.
Crescent R. Isham et al. Blood 2007;109:2579-2588
©2007 by American Society of Hematology
Patient myeloma cells treated in whole bone marrow cell–mixed culture are selectively killed by
chaetocin in comparison to other bone marrow leukocytes, and chaetocin has in vivo
antimyeloma activity.
Crescent R. Isham et al. Blood 2007;109:2579-2588
©2007 by American Society of Hematology
Chaetocin is rapidly and dramatically accumulated in cancer cells by means that require
intact/unreduced chaetocin disulfide bonds.
Crescent R. Isham et al. Blood 2007;109:2579-2588
©2007 by American Society of Hematology
Unlike HDAC inhibitors, chaetocin-induced reductions in A549 cell-colony formation are
attenuated by cotreatment with glutathione or NAC. (A) Glutathione or NAC, but not inhibitors of
DNA (aphidicolin), RNA (DRB), or protein (cycloheximide) synthesis, atten...
Crescent R. Isham et al. Blood 2007;109:2579-2588
©2007 by American Society of Hematology
Chaetocin induces oxidative stress in A549 cells without substantial depletion of intracellular
reduced glutathione levels, whereas the selective cytotoxicity of chaetocin in freshly collected
myeloma cells appears to be attributable to their increased sens...
Crescent R. Isham et al. Blood 2007;109:2579-2588
©2007 by American Society of Hematology